Literature DB >> 21540594

Hypothermic ante situm resection in tumors of the hepatocaval confluence.

Ari Mehrabi1, Hamid Fonouni, Mohammad Golriz, Stefan Hofer, Mohammad Hafezi, Nuh N Rahbari, Jürgen Weitz, Markus W Büchler, Jan Schmidt.   

Abstract

Primary liver malignancies together with metastatic liver tumors are among the most common tumors in human. The best available treatment option for these diseases is surgical resection. One major parameter which had been considered as contraindication for liver resection owing to technical difficulties in achieving tumor-free margins was the involvement of the hepatocaval confluence. To overcome this problem, several techniques including hypothermic in situ, ante situm and ex situ liver resection have been introduced. The common basis for these liver resections is the total vascular exclusion of the liver, and perfusion of the organ by preservation solution under hypothermic conditions. The major indications for the ante situm liver resection are tumors in the liver that are either unresectable or inadequately resectable by conventional surgery because they involve the venous confluence and/or the retrohepatic vena cava, or are in close proximity to them. This technique is a realistic option to achieve surgical cure or substantial gain of life time with quality of life in otherwise unresectable tumors of the liver. Due to fewer anastomoses, the ante situm approach is easier and safer than the ex situ approach, with an acceptable morbidity and mortality rate. Patient selection is of utmost importance to achieve a good outcome. To minimize the postoperative morbidities and mortality, this procedure requires a multidisciplinary approach and should be performed in experienced centers with a high case volume of hepatobiliary surgeries.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21540594     DOI: 10.1159/000323818

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  7 in total

Review 1.  [Vascular replacement in abdominal tumor surgery].

Authors:  A Mehrabi; P Houben; N Attigah; D Böckler; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

Review 2.  Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine.

Authors:  Taizo Hibi; Masahiro Shinoda; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-05-16       Impact factor: 2.500

3.  Modified ante situm liver resection without use of cold perfusion nor veno-venous bypass for treatment of hepatic lesions infiltrating the hepatocaval confluence.

Authors:  F Oldhafer; K I Ringe; K Timrott; M Kleine; O Beetz; W Ramackers; S Cammann; J Klempnauer; F W R Vondran; H Bektas
Journal:  Langenbecks Arch Surg       Date:  2018-02-22       Impact factor: 3.445

4.  Ante situm liver resection with inferior vena cava replacement under hypothermic cardiopolmunary bypass for hepatoblastoma: Report of a case and review of the literature.

Authors:  Roberta Angelico; Annalisa Passariello; Michele Pilato; Tommaso Cozzolino; Marcello Piazza; Roberto Miraglia; Paolo D'Angelo; Mariella Capasso; Maria Cristina Saffioti; Daniele Alberti; Marco Spada
Journal:  Int J Surg Case Rep       Date:  2017-06-13

5.  Surgical management of liver diseases invading the hepatocaval confluence based on IH classification: The surgical guideline in our center.

Authors:  Wei Li; Jun Han; Zhao-Ping Wu; Hong Wu
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

6.  Liver resection combined with inferior vena cava resection and reconstruction using artificial vascular graft: A literature review.

Authors:  Yoshito Tomimaru; Hidetoshi Eguchi; Hiroshi Wada; Yuichiro Doki; Masaki Mori; Hiroaki Nagano
Journal:  Ann Gastroenterol Surg       Date:  2018-04-15

7.  Long-Term Outcomes of Ante-Situm Resection and Auto-Transplantation in Conventionally Unresectable Hepatocellular Carcinoma: A Single-Center Experience.

Authors:  Qifa Ye; Cheng Zeng; Yanfeng Wang; Yingzi Ming; Qiquan Wan; Shaojun Ye; Yan Xiong; Ling Li
Journal:  Ann Transplant       Date:  2018-01-30       Impact factor: 1.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.